Skip to content
2000
Volume 5, Issue 1
  • ISSN: 1574-8898
  • E-ISSN: 2212-3954

Abstract

For decades, the struggle against inflammation and related disorders has constituted an important field in medical practice, with strategies mainly aimed to inhibit the compounds produced through the arachidonic acid pathway. Thus, specific COX-2 inhibitors or “coxibs”, have been recently designed that play an important but controversial role in reducing inflammatory phenomenon. Lately, several patents have been generated which target the specific inhibition of microsomal Prostaglandin E synthase-1 (mPGES-1). This enzyme, which was cloned and characterized at the end of nineties, catalyzes under inflammatory stimuli the last step of PGE2 synthesis. A corpus of data is now available, illustrating the pivotal role played by this enzyme in numerous symptoms linked to inflammation such as fever, anorexia or pain. The present review highlights the current state of knowledge of the involvement of mPGES-1 in sickness behaviour and in other inflammation-related disorders and summarizes the recent patents related to mPGES-1 and its specific inhibition.

Loading

Article metrics loading...

/content/journals/prn/10.2174/157488910789753549
2010-01-01
2025-10-20
Loading full text...

Full text loading...

/content/journals/prn/10.2174/157488910789753549
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test